香港股市 已收市

Merck & Co., Inc. (MRK)

NYSE - Nasdaq 即時價格。貨幣為 USD。
加入追蹤清單
91.02+2.09 (+2.35%)
收市價: 04:03PM EDT
91.24 +0.22 (+0.24%)
收市後: 07:57PM EDT

我們致力為用戶建立安全而有趣的平台,讓他們與志同道合的用戶聯繫交流。為改善我們的社群體驗,我們將會在8月15日停用留言功能。

登入即可發佈回覆。

Yahoo有權移除任何不符 規範服務條款(包括粗俗或鼓勵犯法)之留言。

  • C
    Cured
    $SLS conversation
    Smart money has been accumulating and will continue to accumulate all the way to the FDA Green light a couple few quarters away.
    Ceo on a drunken sailor hiring spree doesn't at all seem worried about money - for some reason.
    1. The July 3d med filing stated they are joining the REGAL P3 - That is a $5M Milestone payment by itself.
    Then you have the P1 Safety for 1m, and the P2 for five indications is another 2 or 3, then the Gps + Envafolimub (approved already in china) combination for another couple/few million.
    2. $BMY $MRK Already had one Opdivo GPs trial stopped early due to efficacy, two more with clinically significant efficacy results with readouts in the next month - "joint analysis at an upcoming medical conference" for the Keytruda PH2 Trial could easily generate 50M in upfront money for ovarian cancer.
  • J
    Joe
    $SLS conversation
    $MRK $BMY. we continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights
  • j
    james
    $SLS conversation
    Speaking of the $MRK expanded partnership and license, don’t forget $BMY. Mesohope article: ‘..results of this [gp-s opdivo] single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks. Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.’

    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    Dr. Zauderer The Mesothelioma Dept chair at Memorial Sloan Kettering is investigating Gps combined w Opdivo for refractory patients, who have exhausted all options. Gps + Opdivo safety has been established, with no grade 3/4 and very few side effects beyond standard vaccination related symptoms.
    No brainer BMY is interested in combining Opdivo a CP Inhibitor, that removes the immune systems' brakes with Gps, the most effective t cell generation agent for 20 WT1 cancers. Gps has demonstrated broad spectrum epitope spread with B Cell cd3 Memory T cells, the hall mark of an effective long term, durable survival extension, in every trial.

    Therapy benefits of 10.5 months / 45.5 weeks vs 22* currently. Gps is already extending os rates nearly 5 months for sicker patients than what Opdivo + Yervoy was approved for in healthier patients.
    - Opdivo Yervoy recently Fda approved after extending survival 4 months for these patients in the front line setting.

    https://www.fiercepharma.com/pharma/wclc-bms-opdivo-yervoy-duo-slashes-mesothelioma-death-risk-by-26
    ". helping them live a median four months longer than those in the study’s chemo arm."

    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

    Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    www.fiercepharma.com
  • C
    Cured
    $SLS conversation
    Simple investment thesis: Super low float, cash for almost 2 years, more coming + 3 Trial studies to report in the next quarter $MRK $BMY CDK9, along with an AML FDA Green light in Q1/2, by all accounts worth billions.

    Upcoming News:
    Now that the REGAL Phase 3 is in the Home stretch, a mere ReIteration of the Phase 3 Results Timeline will launch this baby bio.

    Seriously, is a quarter or 2 a long time to wait for a 2,500% Return on an Investment?

    MD Andersons Leukemia depart chairman running the Ph 3, who sees all the open label trial results, requesting Expanded Access, confirms 2 things; 1. Gps is doing what it has done in every trial, cure patients and extend survival well beyond existing treatment, and 2. Guarantees Immediate off-label prescription and ultimate FDA Approved Expanded label to Cr1 / PostASCT which is 5x the $200M Cr2 initial niche revenue projected by CF.

    95% of drugs w EAP’s get FDA approved.

    Hello!
  • C
    Cured
    $SLS conversation
    Illustrates how over shorted $SLS is right now $Blte Phase 2 8 of 13 patients respond; Compare that to the $mrk Phase 2 trial Combining Gps with Keytruda, Final Data now due, with an overall survival duration that will far surpass all other ovarian cancer treatments. Or the MSK Mesothelioma data that again is better than all other treatments - Not to mention the FDA Green Light is a quarter or two away with the results of Phase 3 AML Trial.
    https://www.biopharmadive.com/news/belite-bio-stargardt-dry-AMD-drugmaker-biotech-best-performing-ipo/628589/
    Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.
    Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.
    www.biopharmadive.com
  • C
    Cured
    $SLS conversation
    3 ongoing, active Immunotherapy Trials in End stage, platinum resistant/refractory;
    1. In combination w $MRK Keytruda in Ovarian Cancer and
    2. in combination $BMY w Opdivo in Mesothelioma and also 3. a nearly complete Phase 3 trial to extend and prolong remission for patients in Secondary AML Remission.

    3D Med currently initiating 5 Gps trials in Greater china, as a monotherapy and in combination w Envafolimub, the first injectable Checkpoint inhibitor.

    Current Status: for 2.
    GPs Opdivo combination for end stage Mesothelioma patients; 10.5 months of median survival reported in June vs 22 weeks w current standard of care. Gps Opdivo median os has not yet been reached as more than half the patients continue to survive.
    This data is already causing great excitement within the community
    https://www.asbestos.com/news/2022/06/14/novel-clinical-trial-helping-late-stage-mesothelioma-patients/
    Google Galinpepimut-S and Opdivo for several others.

    While it's relatively easy, in the short run to manipulate the SLS share price in the long run, the true value will be realized. And it's significant, not just for SLS but Mrk BMY and many other big pharma developing Check point inhibitors.
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    www.asbestos.com
  • C
    Cured
    $SLS conversation
    $mrk or $bmy are Going to buy this.
    Be Holding
  • C
    Cured
    $SLS conversation
    SLS $MRK Joint Analysis
    Immunological data supporting the specific action of GPS in extending disease free survival and overall survival. These data are being analyzed by Merck and are going to presented in an 'upcoming medical conference'...so quite soon (July-August?) https://www.reddit.com/r/sellaslifesciences/comments/uy75zj/from_angelo_on_ovariancancer_combo_data_keytruda/
  • C
    Cured
    $SLS conversation
    This is the latest from Angelo on Ovarian Cancer Data (Keytruda $MRK + GPS)
    'I am excited to share our top-line data from our combination study of GPS with the checkpoint inhibitor pembrolizumab in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. With 43.1 weeks of follow-up, the median overall survival among the patients in this trial has not yet been reached and the median progression-free survival was 12 weeks. This compares favorably to 8.4 weeks for pembrolizumab alone seen in a similar platinum-resistant ovarian cancer patient population in the KEYNOTE-100 study - a 43 percent increase in the GPS combination with pembrolizumab. The disease control rate was 53.9 percent – in comparison, in the KEYNOTE-100 study, the observed disease control rate was 37.2% - a 45% increase in the GPS combination with pembrolizumab.

    In this exceedingly difficult to treat patient population with active disease, the combination of GPS and pembrolizumab seems to be effective at halting or slowing down progression. GPS has typically been utilized in the remission setting and to see such intriguing data in combination with pembrolizumab in active disease is indeed exciting. I would like to wholeheartedly thank all patients for participating in the study as well as their physicians, nurses, and study teams as well as our teams at SELLAS and Merck.'

    As a note: The median overall survival is the time — expressed in months or years — when half the patients are expected to be alive. In our case it means that after 43 weeks (around > 10 months) we still have more than 50% (in a range that goes from 51 to 100%) of the patients alive, thus the median overall survival has not been reached: good stuff...

    Its either $mrk or $BMY
  • A
    A.I.R.
    A tweet:

    So $MRK is looking to buy $SGEN at a valuation that would be 20x sales. That is not going to end well for $MRK. Reminds of the $GILD purchase of $IMMU for $21 billion which was a disaster.
  • J
    Joe
    $SLS conversation
    You want to know what the deal is for SLS look at $plrx up from 4 to 20 in a week on Trial Results - SlS reporting Joint Analysis Data with $mrk in July/Aug time frame is worth 10x the whole SLS market cap.
  • D
    Dude
    $SLS conversation
    Gps was included as future Revenue Generator for $BMY? SlS shares are a steal. $mrk bmy bidding war.
    https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again
  • m
    marco
    $VBIV conversation
    Could $MRK buyout $VBIV in 2022?
    VBI Vaccines is set to become a leader in the areas of Hep-B + GBM. Their COVID pipeline coming up for VBI-2905 data will validate further NRC & CEPI funding.

    This plausible speculation has a lot of extensive DD done to come to the conclusion that Merck will either buyout $VBIV or do a major partnership for theor Hep-B & oncology pipeline.

    CEO remarks last Call:

    "But we're really excited about the TRIPLE COMBINATION when it reads out in the second half of this year through our colleagues at Brii and what informs for the rest of the world. We VBI has retained Ex-China rights to this. Once we have some data, if it is successful, touch-wood, then WE WILL HAVE SOME INTERESTING DISCUSSIONS WITH SOME OTHER PLAYERS WHO LOOK TO MAKE SIGNIFICANT MOVES IN THIS FIELD FOR THE REST OF WORLD RIGHTS."

    https://www.reddit.com/r/VBIV/comments/tp2wi3/merck_potential_buyout_candidate_for_vbiv_dd_by/
  • D
    Dennis
    $MRK conversation
    $MRK. Thanks for the divvy; DRIP
  • C
    Cured
    $SLS conversation
    $bmy $mrk b like
    Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is 28 Weeks
  • P
    P509$
    $SLS conversation
    Kind of deal I expect we'll see here $BMY is competing with $MRK - Gps gives both companies an effective therapy for Ovarian cancer.
    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/
  • S
    Stephens
    $SLS conversation
    Serious: If the DMC doesn't stop the P3 early for Efficacy and SLS isn't bought by $MRK or $BMY
    What will SLS' market value be when the FDA gets a look at the AML results? When is that?
    Lastly, when will the market begin to appreciate SLS shares in advance of that massively valuable inflection point?
  • B
    Berlin 68
    $XBI conversation
    SLS diverging / up nicely, with shorts covering all what they sold the last couple weeks to hold it down, after great trial data with $MRK $BMY. SLS Is ripe for a squeeze.
  • C
    Cured
    $SLS conversation
    A reminder, $mrk Has no other trials for these Platinum Refractor patients, Keytruda ineffective alone, and not one other Merck Partnership is in trial - Gps +Keytruda has a 54% Disease Control rate and a median Os yet to be reached, but already longer than all other therapies.
    All enrolled patients were resistant to standard of care platinum-based therapy and 78.5 percent of evaluable patients were refractory to or had failed their first- or second-line therapies with 21.5 percent having failed three or more lines of therapy, including one patient who failed five previous lines of therapy. Of the 15 patients, 13 received at least three doses of GPS, the last of which was in combination with pembrolizumab, and were evaluable for response outcomes.

    Summary of Top-Line Clinical Data
    An ad hoc analysis of clinical outcomes in this cohort shows a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 53.9 percent at a median follow-up of 43.1 weeks. In a checkpoint inhibitor single agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2 percent, consistent with a DCR rate increase of 45 percent in the GPS combination with pembrolizumab over that seen for checkpoint inhibitors alone.
    Median progression-free survival (PFS) was 12 weeks compared to 8.4 weeks for checkpoint inhibitors alone seen in studies with similar patient populations, a 43 percent increase in the GPS combination with pembrolizumab. Patients with fewer previous lines of chemotherapy experienced a more favorable median PFS than those with more than two previous lines: for patients with two or fewer previous lines of therapy treated with GPS in combination with pembrolizumab, median PFS was 24 weeks.
    With 43.1 weeks of follow-up the median overall surviva
  • T
    Thomas
    Merck & Co., Inc.
    Load up people $MRK Getting ready to take off